In a previous study, as an alternative to the existing osteoporosis treatments, we developed a recombinant protein delivery system using 30Kc19α‐RUNX2, which differentiates human mesenchymal stem cells (hMSCs) into osteoblasts.[5] 30Kc19α‐RUNX2 is a fusion protein of runt‐related transcription factor 2 (RUNX2), a key transcription factor for osteoblast differentiation, and 30Kc19α, a cell‐penetrating protein. The gene discussed is RUNX2; the disease is osteoporosis.